{"id":388936,"date":"2020-11-26T12:33:20","date_gmt":"2020-11-26T17:33:20","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=388936"},"modified":"2020-11-26T12:33:20","modified_gmt":"2020-11-26T17:33:20","slug":"tmx-group-antibe-therapeutics-c-suite-at-the-open","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tmx-group-antibe-therapeutics-c-suite-at-the-open\/","title":{"rendered":"TMX Group, Antibe Therapeutics, C-Suite at The Open"},"content":{"rendered":"
\n

Canada NewsWire<\/p>\n<\/p><\/div>\n

\n

\n TORONTO<\/span>, Nov. 26, 2020<\/span> \/CNW\/ – Dan Legault<\/span>, CEO, Antibe Therapeutics Inc. (TSX: ATE), shares his\u00a0company’s\u00a0story in an interview<\/a><\/b>\u00a0with TMX Group.<\/p>\n

\n

The C-Suite at The Open video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange.\u00a0 Videos provide insight into how company executives think in the current business environment.\u00a0 To see the latest C-Suite at The Open videos visit https:\/\/www.tmxmoney.com\/en\/csuite.html<\/a>.<\/p>\n

\n
\n About Antibe Therapeutics Inc.\u00a0 (TSX: ATE)
<\/u>
\n <\/b>\n <\/p>\n

Antibe Therapeutics Inc. develops safer, non-addictive medicines for pain and inflammation. Its technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved and patented medicine. The company’s drug, ATB-346, targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in pipeline, targets the urgent global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. Its operating segment includes Antibe and Citagenix. The company generates maximum revenue from Citagenix segment and geographically from Canada<\/span>. Citagenix segment is a marketer and distributor of regenerative medicines serving the dental and orthopaedic market places. For more information visit: http:\/\/www.antibethera.com\/<\/a>\u00a0<\/p>\n

\n
\n About TMX Group (TSX: X)<\/u>
\n <\/b>\n <\/p>\n

TMX Group’s key subsidiaries operate cash and derivative markets and clearinghouses for multiple asset classes including equities and fixed income. Toronto Stock Exchange<\/a><\/u>, TSX Venture Exchange<\/a><\/u>, TSX Alpha Exchange<\/a><\/u>, The Canadian Depository for Securities<\/a><\/u>, Montr\u00e9al Exchange<\/a><\/u>, Canadian Derivatives Clearing Corporation<\/a><\/u>, Trayport<\/a><\/u>\u00a0and other TMX Group companies provide listing markets, trading markets, clearing facilities, depository services, technology solutions, data products and other services to the global financial community. TMX Group is headquartered in Toronto<\/span> and operates offices across North America<\/span> (Montr\u00e9al, Calgary<\/span>, Vancouver<\/span> and New York<\/span>), as well as in key international markets including London<\/span>, Beijing<\/span> and Singapore<\/span>. For more information about TMX Group, visit our website at www.tmx.com<\/a><\/u>. Follow TMX Group on Twitter: @TMXGroup<\/a><\/u>.<\/p>\n

SOURCE TMX Group Limited<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Canada NewsWire TORONTO, Nov. 26, 2020 \/CNW\/ – Dan Legault, CEO, Antibe Therapeutics Inc. (TSX: ATE), shares his\u00a0company’s\u00a0story in an interview\u00a0with TMX Group. The C-Suite at The Open video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange.\u00a0 Videos provide insight into how company executives think in the current business environment.\u00a0 To see the latest C-Suite at The Open videos visit https:\/\/www.tmxmoney.com\/en\/csuite.html. About Antibe Therapeutics Inc.\u00a0 (TSX: ATE) Antibe Therapeutics Inc. develops safer, non-addictive medicines for pain and inflammation. Its technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved and patented medicine. The company’s drug, ATB-346, targets the global need for a safer, non-addictive drug for … <\/p>\n

Continue reading “TMX Group, Antibe Therapeutics, C-Suite at The Open”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-388936","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTMX Group, Antibe Therapeutics, C-Suite at The Open - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tmx-group-antibe-therapeutics-c-suite-at-the-open\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TMX Group, Antibe Therapeutics, C-Suite at The Open - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Canada NewsWire TORONTO, Nov. 26, 2020 \/CNW\/ – Dan Legault, CEO, Antibe Therapeutics Inc. (TSX: ATE), shares his\u00a0company’s\u00a0story in an interview\u00a0with TMX Group. The C-Suite at The Open video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange.\u00a0 Videos provide insight into how company executives think in the current business environment.\u00a0 To see the latest C-Suite at The Open videos visit https:\/\/www.tmxmoney.com\/en\/csuite.html. About Antibe Therapeutics Inc.\u00a0 (TSX: ATE) Antibe Therapeutics Inc. develops safer, non-addictive medicines for pain and inflammation. Its technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved and patented medicine. The company’s drug, ATB-346, targets the global need for a safer, non-addictive drug for … Continue reading "TMX Group, Antibe Therapeutics, C-Suite at The Open"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tmx-group-antibe-therapeutics-c-suite-at-the-open\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-26T17:33:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=C1900&Transmission_Id=202011261230CANADANWWEB______C1900&DateId=20201126\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tmx-group-antibe-therapeutics-c-suite-at-the-open\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tmx-group-antibe-therapeutics-c-suite-at-the-open\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"TMX Group, Antibe Therapeutics, C-Suite at The Open\",\"datePublished\":\"2020-11-26T17:33:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tmx-group-antibe-therapeutics-c-suite-at-the-open\\\/\"},\"wordCount\":338,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tmx-group-antibe-therapeutics-c-suite-at-the-open\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/rt.prnewswire.com\\\/rt.gif?NewsItemId=C1900&Transmission_Id=202011261230CANADANWWEB______C1900&DateId=20201126\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tmx-group-antibe-therapeutics-c-suite-at-the-open\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tmx-group-antibe-therapeutics-c-suite-at-the-open\\\/\",\"name\":\"TMX Group, Antibe Therapeutics, C-Suite at The Open - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tmx-group-antibe-therapeutics-c-suite-at-the-open\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tmx-group-antibe-therapeutics-c-suite-at-the-open\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/rt.prnewswire.com\\\/rt.gif?NewsItemId=C1900&Transmission_Id=202011261230CANADANWWEB______C1900&DateId=20201126\",\"datePublished\":\"2020-11-26T17:33:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tmx-group-antibe-therapeutics-c-suite-at-the-open\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tmx-group-antibe-therapeutics-c-suite-at-the-open\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tmx-group-antibe-therapeutics-c-suite-at-the-open\\\/#primaryimage\",\"url\":\"https:\\\/\\\/rt.prnewswire.com\\\/rt.gif?NewsItemId=C1900&Transmission_Id=202011261230CANADANWWEB______C1900&DateId=20201126\",\"contentUrl\":\"https:\\\/\\\/rt.prnewswire.com\\\/rt.gif?NewsItemId=C1900&Transmission_Id=202011261230CANADANWWEB______C1900&DateId=20201126\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tmx-group-antibe-therapeutics-c-suite-at-the-open\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TMX Group, Antibe Therapeutics, C-Suite at The Open\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TMX Group, Antibe Therapeutics, C-Suite at The Open - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tmx-group-antibe-therapeutics-c-suite-at-the-open\/","og_locale":"en_US","og_type":"article","og_title":"TMX Group, Antibe Therapeutics, C-Suite at The Open - Market Newsdesk","og_description":"Canada NewsWire TORONTO, Nov. 26, 2020 \/CNW\/ – Dan Legault, CEO, Antibe Therapeutics Inc. (TSX: ATE), shares his\u00a0company’s\u00a0story in an interview\u00a0with TMX Group. The C-Suite at The Open video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange.\u00a0 Videos provide insight into how company executives think in the current business environment.\u00a0 To see the latest C-Suite at The Open videos visit https:\/\/www.tmxmoney.com\/en\/csuite.html. About Antibe Therapeutics Inc.\u00a0 (TSX: ATE) Antibe Therapeutics Inc. develops safer, non-addictive medicines for pain and inflammation. Its technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved and patented medicine. The company’s drug, ATB-346, targets the global need for a safer, non-addictive drug for … Continue reading \"TMX Group, Antibe Therapeutics, C-Suite at The Open\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tmx-group-antibe-therapeutics-c-suite-at-the-open\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-26T17:33:20+00:00","og_image":[{"url":"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=C1900&Transmission_Id=202011261230CANADANWWEB______C1900&DateId=20201126","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tmx-group-antibe-therapeutics-c-suite-at-the-open\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tmx-group-antibe-therapeutics-c-suite-at-the-open\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"TMX Group, Antibe Therapeutics, C-Suite at The Open","datePublished":"2020-11-26T17:33:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tmx-group-antibe-therapeutics-c-suite-at-the-open\/"},"wordCount":338,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tmx-group-antibe-therapeutics-c-suite-at-the-open\/#primaryimage"},"thumbnailUrl":"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=C1900&Transmission_Id=202011261230CANADANWWEB______C1900&DateId=20201126","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tmx-group-antibe-therapeutics-c-suite-at-the-open\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tmx-group-antibe-therapeutics-c-suite-at-the-open\/","name":"TMX Group, Antibe Therapeutics, C-Suite at The Open - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tmx-group-antibe-therapeutics-c-suite-at-the-open\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tmx-group-antibe-therapeutics-c-suite-at-the-open\/#primaryimage"},"thumbnailUrl":"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=C1900&Transmission_Id=202011261230CANADANWWEB______C1900&DateId=20201126","datePublished":"2020-11-26T17:33:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tmx-group-antibe-therapeutics-c-suite-at-the-open\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tmx-group-antibe-therapeutics-c-suite-at-the-open\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tmx-group-antibe-therapeutics-c-suite-at-the-open\/#primaryimage","url":"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=C1900&Transmission_Id=202011261230CANADANWWEB______C1900&DateId=20201126","contentUrl":"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=C1900&Transmission_Id=202011261230CANADANWWEB______C1900&DateId=20201126"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tmx-group-antibe-therapeutics-c-suite-at-the-open\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"TMX Group, Antibe Therapeutics, C-Suite at The Open"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=388936"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388936\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=388936"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=388936"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=388936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}